166 related articles for article (PubMed ID: 25332032)
1. Optimising the expansion of the National Bowel Cancer Screening Program.
Cenin DR; St John DJ; Ledger MJ; Slevin T; Lansdorp-Vogelaar I
Med J Aust; 2014 Oct; 201(8):456-61. PubMed ID: 25332032
[TBL] [Abstract][Full Text] [Related]
2. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
[TBL] [Abstract][Full Text] [Related]
3. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
[TBL] [Abstract][Full Text] [Related]
4. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
Ee H; St John J
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
[TBL] [Abstract][Full Text] [Related]
5. Survival impact of the Australian National Bowel Cancer Screening Programme.
Ananda S; Wong H; Faragher I; Jones IT; Steele M; Kosmider S; Desai J; Tie J; Field K; Wong R; Tran B; Bae S; Gibbs P
Intern Med J; 2016 Feb; 46(2):166-71. PubMed ID: 26418334
[TBL] [Abstract][Full Text] [Related]
6. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
[TBL] [Abstract][Full Text] [Related]
7. Impact of a mass media campaign on participation rates in a National Bowel Cancer Screening Program: a field experiment.
Durkin SJ; Broun K; Spittal MJ; Wakefield MA
BMJ Open; 2019 Jan; 9(1):e024267. PubMed ID: 30813110
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
[TBL] [Abstract][Full Text] [Related]
9. The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program.
Wood A; Emery JD; Jenkins M; Chondros P; Campbell T; Wenkart E; O'Reilly C; Cowie T; Dixon I; Toner J; Khalajzadeh H; Gutierrez JM; Govan L; Buckle G; McIntosh JG
Trials; 2022 Jan; 23(1):31. PubMed ID: 35022080
[TBL] [Abstract][Full Text] [Related]
10. Colonoscopies in Australia - how much does the National Bowel Cancer Screening Program contribute to colonoscopy use?
Worthington J; He E; Lew JB; St John J; Horn C; Grogan P; Canfell K; Feletto E
Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36477980
[TBL] [Abstract][Full Text] [Related]
11. Screening colonoscopy in Australia.
Singh R; Mangira D; Kawano H; Matsuda T
Dig Endosc; 2015 Apr; 27 Suppl 1():30-4. PubMed ID: 25523496
[TBL] [Abstract][Full Text] [Related]
12. Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Greuter MJE; Coupé VMH; Canfell K
Cancer Epidemiol Biomarkers Prev; 2018 Dec; 27(12):1450-1461. PubMed ID: 30190276
[TBL] [Abstract][Full Text] [Related]
13. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
[TBL] [Abstract][Full Text] [Related]
14. Improving colonoscopy prioritisation and promoting the National Bowel Cancer Screening Program: keys to reducing bowel cancer burden.
Grogan P; He E; Pockney P
Public Health Res Pract; 2023 Mar; 33(1):. PubMed ID: 36918394
[TBL] [Abstract][Full Text] [Related]
15. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.
Pignone MP; Flitcroft KL; Howard K; Trevena LJ; Salkeld GP; St John DJ
Med J Aust; 2011 Feb; 194(4):180-5. PubMed ID: 21401458
[TBL] [Abstract][Full Text] [Related]
16. Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia.
Worthington J; Feletto E; Lew JB; Broun K; Durkin S; Wakefield M; Grogan P; Harper T; Canfell K
Public Health; 2020 Feb; 179():90-99. PubMed ID: 31760206
[TBL] [Abstract][Full Text] [Related]
17. Engaging lower screening groups: a field experiment to evaluate the impact of a multiwave national campaign on participation in the National Bowel Cancer Screening Program.
Gascoyne C; Broun K; Morley B; Wyatt K; Feletto E; Durkin SJ
BMJ Open; 2023 Mar; 13(3):e065124. PubMed ID: 36921953
[TBL] [Abstract][Full Text] [Related]
18. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
[TBL] [Abstract][Full Text] [Related]
19. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model.
Idigoras I; Arrospide A; Portillo I; Arana-Arri E; Martínez-Indart L; Mar J; de Koning HJ; Lastra R; Soto-Gordoa M; van der Meulen M; Lansdorp-Vogelaar I
BMC Public Health; 2017 Aug; 18(1):78. PubMed ID: 28764731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
